Enzo Biochem Inc. | Mutual Funds
Mutual Funds that own Enzo Biochem Inc.
Evermore Global Value fund
3,920,249
8.31%
100,993
3.11%
03/31/2018
Vanguard Total Stock Market Index Fund
1,674,789
3.55%
399,700
0%
07/31/2018
Engex Fund
1,216,196
2.58%
0
72.23%
12/31/2017
iShares Russell 2000 ETF
921,763
1.95%
-492
0.01%
09/06/2018
DFA US Small Cap Portfolio
692,415
1.47%
0
0.01%
04/30/2018
CREF Stock Account
649,379
1.38%
16,055
0%
03/31/2018
Vanguard Extended Market Index Fund
590,984
1.25%
-102
0%
07/31/2018
iShares Russell 2000 Growth ETF
432,635
0.92%
0
0.02%
09/06/2018
DFA US Micro Cap Portfolio
362,030
0.77%
0
0.02%
04/30/2018
British Columbia Inv Management Corp.
252,872
0.54%
-9,600
0%
03/31/2017
| Address |
60 Executive Boulevard
New York New York 11735
United States
|
|
Employees
|
- |
| Website |
http://www.enzo.com |
| Updated |
07/08/2019 |
| Enzo Biochem, Inc. engages in the research, development, and market of pharmaceutical products. Its medicines target the following conditions: inflammatory bowel disease, uveitis, human immunodeficiency virus, diabetes, and bone disorders. The company was founded by Elazar Rabbani, Barry W. |
